WO2026104995 - DETECTION OF METHYLATED LUNG CANCER TUMOR DNA
National phase entry is expected:
Publication Number
WO/2026/104995
Publication Date
21.05.2026
International Application No.
PCT/IB2025/061529
International Filing Date
11.11.2025
Title **
[English]
DETECTION OF METHYLATED LUNG CANCER TUMOR DNA
[French]
DÉTECTION DE L'ADN TUMORAL MÉTHYLÉ DANS LE CANCER PULMONAIRE
Applicants **
MDETECT INC.
MUELLER, Christopher R.
Inventors
MUELLER, Christopher R.
Priority Data
63/719,487
12.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4285 | |
| EPO | Filing, Examination, Granting | 30193 | |
| Japan | Filing, Examination, Granting | 2927 | |
| South Korea | Filing, Examination, Granting | 3799 | |
| USA | Filing, Examination, Granting | 13090 |
Total:
54,294
Contact Us
Abstract[English]
Disclosed are methods and a kit for monitoring disease state of a lung cancer, including non-small cell lung cancer. The methods include determination of methylation status of cell-free DNA, with methylation being representative of tumor burden. The method can also be used to monitor the efficacy of a cancer treatment regime.[French]
La présente invention concerne des procédés et un kit destinés au suivi de l'évolution d'un cancer pulmonaire, y compris le cancer pulmonaire non à petites cellules. Ces procédés consistent notamment à déterminer le statut de méthylation de l'ADN acellulaire, la méthylation étant représentative de la charge tumorale. Ce procédé peut également servir au suivi de l'efficacité d'un traitement anticancéreux.